期刊文献+

乳腺癌化疗和内分泌治疗是否应当联合使用 被引量:2

Whether the Chemotherapy and Endocrine Therapy ShouldBe Combined in Breast Cancer Treatment
暂未订购
导出
摘要 在乳腺癌治疗中 ,化疗和内分泌治疗是否可以联合应用一直是大家关注及争论的热点。该文分别从术后辅助治疗和复发转移后解救治疗两个方面 ,回顾国际大规模临床试验的结果 ,结合当前乳腺癌治疗的指导原则和作者的经验 ,认为乳腺癌化疗和内分泌治疗应当合理地序贯应用 。 It was always concerned and discussed whether the chemotherapy and endocrine therapy should be or could be combined in breast cancer treatment.The authors reviewed the results of international large_scale clinical trials about chemotherapy and endocrine therapy both in early stage breast cancer and advanced breast cancer.Together with the guideline of treatment to breast cancer and their experiences,the authors indicated that chemotherapy and endocrine therapy in breast cancer can be used sequentially as combination,but not in the same time.
机构地区 军事医学科学院
出处 《肿瘤学杂志》 CAS 2002年第6期315-317,共3页 Journal of Chinese Oncology
关键词 乳腺肿瘤 药物疗法 内分泌疗法 breast neoplasms drug therapy endocrine therapy
  • 相关文献

参考文献8

  • 1Albain KS,Green SJ,Racsin PM,et al.Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent:initial results from intergroup trial 0100(SWOG 8814)[J].Proc Am Soc Clin Oncol,2002,21:37a.
  • 2Pico C,Martin M,Jara C,et al.Epirubicin cyclophosphamide(EC)chemotherapy plus tamoxifen(T)administered concurrent(Con)versus sequential(Sec):randomized phase Ⅲ trial in postmenopausal node positive breast cancer patients.GEICAM9401 study[J].Proc Am Soc Clin Oncol,2002,21:37a.
  • 3Sertoli MR,Pronzato P,Venturini M,et al.A randomized study of concurrent versus sequential adjuvant chemotherapy and tamoxifen in stage Ⅱ breast cancer[J].Proc Am Soc Clin Oncol,2002,21:46a.
  • 4宋三泰.乳癌内分泌治疗的新观点和再认识[J].中国肿瘤临床与康复,2001,8(2):1-2. 被引量:18
  • 5Wolf C,Hackl W,Kuemper S,et al.Exemestane combined with epirubicin,qlw× (8- 12),as preoperative chemoendocrine treatment for patients with primary breast cancer:a phase Ⅰ study[J].Proc Am Soc Clin Oncol,2001,20:18b.
  • 6Lichtenegger W,Hackl W,Huettner C,et al.Exemestane combined with weekly docetaxel as preoperative treatment for breast cancer[J].Proc Am Soc Clin Oncol,2001,20:21b.
  • 7Gennatas C,Mouratidou D,Tsavaris N,et al.Randomized study of docetaxel and mitoxantrone versus docetaxel,mitoxantrone and letrozole as first line therapy in advanced breast cancer[J].Proc Am Soc Clin Oncol,2001,20:46b.
  • 8宋三泰,汤仲明.重视乳癌ER及内分泌治疗的临床研究[J].中华肿瘤杂志,1993,15(2):83-85. 被引量:10

共引文献26

同被引文献19

  • 1江泽飞,宋三泰,李家益,徐建明,刘晓晴,汤仲明.大剂量甲孕酮治疗复发转移乳癌[J].中华肿瘤杂志,1995,17(1):71-73. 被引量:12
  • 2江泽飞,徐兵河,宋三泰,孙燕.乳腺癌内分泌治疗的基本共识[J].中华肿瘤杂志,2006,28(3):238-239. 被引量:49
  • 3Nistico C, Garufi C, Milella M, et al. Weekly schedule of vinorelbine in pretreated breast cancer patients. Breast Cancer Res Treat, 2000, 59: 223-229.
  • 4Zelek L, Barthier S, Riofrio M, et al. Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. Cancer, 2001, 92: 2267-2272.
  • 5Smorenburg CH, Bontenbal M, Seynaeve C, et al. Phase Ⅱ study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane. Breast Cancer Res Treat, 2001, 66: 83-87.
  • 6Rha SY, Moon YH, Jeung HC, et al. Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer. Breast Cancer Res Treat, 2005, 90: 215-221.
  • 7Talbot DC, Moiseyenko V, Van Belle S, et al. Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. BrJ Cancer, 2002, 86: 1367-1372.
  • 8Carlson RW, Allred DC, Anderson BO, et al. Invasive breast cancer. J Natl Compr Canc Netw. 2007, 5:246-312.
  • 9Dunphy FR, Spitzer G, Buzdar AU, et al. Treatment of estrogen receptor-negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support. J Clin Oncol, 1990, 7: 1207-1216.
  • 10Gennatas C, Mouratidou D, Tsavaris N, et al. Randomized study of docetaxel and mitoxantrone versus doxetaxel,mitoxantrone and letozole as first-line therapy in advanced breast cancer. Proc Am Soc Clin Oncol, 2001, 20: 40b.

引证文献2

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部